# Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma

> **NCT03313323** · PHASE2 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 29 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** 89Zirconium-labeled ipilimumab

## Key facts

- **NCT ID:** NCT03313323
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-16
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2021-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03313323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03313323, "Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03313323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*